1Lok ASF, McMahon BJ. Chronic Hepatitis B. Hepatology, 2001, 34:1225-1241.
2Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology,2001,33 : 1527-1532.
3Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology, 2003, 124 :105-117.
4van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B:relatlon to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut, 2003,52:420-424.
5Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology,2003,37 : 748-755.
6Hoofnagle JH. Challenges in therapy of chronic Hepatitis B. EASL International Consensus Conference on Hepatitis B. 13-14 Sep. 2002,Geneva, Switzerland.
7Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology, 2000, 32 : 803-806.
8Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology,2001,33:1527-1532.
9van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut, 2003,52:420-424.
10Lok ASF, McMahon BJ. Chronic Hepatitis B. Hepatology, 2001, 34:1225-1241.
